期刊
MEDICAL JOURNAL OF AUSTRALIA
卷 196, 期 10, 页码 638-641出版社
AUSTRALASIAN MED PUBL CO LTD
DOI: 10.5694/mja11.10981
关键词
-
资金
- National Health and Medical Research Council (NHMRC)
- Health Protection Scotland
- Medical Research Council, UK
- Centre for Research Excellence into Injecting Drug Use
- Economic and Social Research Council [ES/G007543/1] Funding Source: researchfish
- Medical Research Council [G1000021, G0701627] Funding Source: researchfish
- National Institute for Health Research [PDF-2011-04-049, RP-DG-0610-10055] Funding Source: researchfish
- ESRC [ES/G007543/1] Funding Source: UKRI
- MRC [G0701627, G1000021] Funding Source: UKRI
- National Institutes of Health Research (NIHR) [PDF-2011-04-049] Funding Source: National Institutes of Health Research (NIHR)
Objectives: To develop a mathematical model to project the potential impact of hepatitis C virus (HCV) treatment on HCV infection prevalence among people who inject drugs (PWID). Design and setting: An existing model of HCV transmission among PWID was parameterised using data from Victoria, Australia, including specific parameter estimates of the number of people who are currently active injecting drug users, average duration of injecting, chronic HCV infection prevalence among PWID, annual mortality, and annual HCV treatment rate. We also explored the impact of prevalence uncertainty, program scale-up, and new treatments. Main outcome measure: Prevalence of chronic HCV infection among people who are currently active injecting drug users. Results: With annual treatment rates of 13,17, or 25 per 1000 PWID, the model predicts relative prevalence reductions of 20%, 30%, and 50%, respectively, within 30 years. If new treatments giving higher sustained viral response rates are available in 5 years, estimated impact is increased by 21%-23% at 15 years, and 17%-38% at 30 years, depending on treatment rates. Conclusions: This model suggests that modest rates of current HCV treatment among PWID in Victoria, Australia could halve HCV infection prevalence among PWID in 30 years. This finding suggests that interventions aimed at increasing access to HCV treatment in community clinics will benefit individual PWID and reduce HCV infection prevalence.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据